Introduction: Who Should Seek Diagnostic Testing

Anyone who notices a new growth or spot on their skin should pay close attention, especially if it doesn’t go away within a few days. If you see a bump or mark on your skin that persists for more than five days, it’s time to visit your doctor for evaluation.^[1] Nodular melanoma can develop quickly, often growing noticeably over just several weeks or months, so early detection is crucial.^[1]

People who have certain risk factors should be especially vigilant about skin changes. You should seek diagnostic testing if you’re a man over 50 years old, as this group faces higher risk.^[1] Additionally, if you have fair skin that burns easily, spend a lot of time in the sun, have had skin cancer before, or have a family history of skin cancer, you should monitor your skin closely and consult a doctor about any suspicious changes.^[1]

Nodular melanoma often appears as a firm, dome-shaped growth on the skin that may be black, red, pink, brown, blue-black, or even the same color as your surrounding skin.^[1] Unlike other types of melanoma, nodular melanoma doesn’t always follow the typical warning signs that doctors teach patients to watch for. Most melanomas have features like asymmetry, uneven borders, multiple colors, or irregular shapes. However, nodular melanomas are different—they usually appear as round bumps with even borders and solid coloring.^[2] This makes them trickier to identify, which is why it’s important not to wait if you notice any new, rapidly growing bump on your skin.

It’s worth noting that nodular melanoma most commonly develops on parts of the body that receive a lot of sun exposure, including your legs, chest, back, belly, arms, and head.^[1] However, it can appear anywhere on your body. The growths are usually larger than typical moles, generally measuring more than 1 centimeter across—about the length of a staple—and raised more than 6 millimeters above the skin surface.^[1]

Classic Diagnostic Methods

Initial Clinical Examination

The diagnostic journey for nodular melanoma typically begins with a visit to a dermatologist, a doctor who specializes in skin conditions. During this initial appointment, the dermatologist will carefully examine your skin, looking at the suspicious spot or bump in detail.^[1] This visual inspection is the first step in determining whether the growth might be nodular melanoma or another condition.

Because nodular melanomas can look similar to benign (non-cancerous) skin conditions like blood blisters, moles, bug bites, or even pimples, trained medical professionals use special techniques to distinguish them from harmless growths.^[1] The doctor will assess various features of the lesion, including its color, shape, size, texture, and how quickly it has been growing.

Dermoscopy

One valuable tool that dermatologists use during examination is called a dermatoscope. This handheld device allows the doctor to look at the skin lesion in much greater detail than is possible with the naked eye.^[3] When a dermatologist or other doctor trained in its use examines a suspicious spot with dermoscopy, they can see features that help distinguish nodular melanoma from other skin conditions, such as regular moles, age spots, basal cell carcinoma (another type of skin cancer), or blood vessel lesions.^[3]

During dermoscopy, doctors look for specific patterns that suggest nodular melanoma. The most frequently observed features include a disorganized, asymmetrical structure, unusual patterns in the blood vessels feeding the growth, blue-gray colored areas, and multiple colors present in the lesion.^[3] These visual clues help doctors decide whether a biopsy is necessary.

Biopsy: Confirming the Diagnosis

If the dermatologist suspects nodular melanoma based on the visual examination and dermoscopy findings, they will perform a biopsy. A biopsy is the only way to definitively confirm whether a skin growth is melanoma.^[1] During this procedure, the doctor removes some or all of the suspicious growth and sends the tissue sample to a laboratory for detailed examination.^[1]

For suspected nodular melanoma, doctors typically perform what’s called an excision biopsy, where they remove the entire lesion if possible.^[3] This approach is preferred because it allows the laboratory to examine the complete growth, providing the most accurate diagnosis. In some cases, if the growth is very large, a doctor might remove just a portion of it, but complete removal is generally recommended when nodular melanoma is suspected.

Once the tissue reaches the laboratory, a doctor called a pathologist examines it under a microscope.^[1] The pathologist looks at the tissue structure and individual cells to determine whether cancer is present. They can identify the specific type of melanoma and measure important features that affect treatment decisions.

Measuring Tumor Thickness

One of the most important measurements the pathologist makes is the thickness of the melanoma—specifically, how deeply it has grown into the layers of your skin.^[1] This measurement, often called the Breslow thickness, is crucial because it helps predict the risk that the cancer will spread to other parts of your body. Thicker tumors have a higher chance of spreading and returning after treatment.^[4]

The thickness measurement helps doctors determine the cancer’s stage. If the melanoma is less than 2 millimeters thick, it’s considered Stage I and is generally low-risk.^[1] When the melanoma is thicker than 2 millimeters, it’s classified as Stage II, which indicates a higher risk of the cancer coming back, although there may still be no evidence that it has spread.^[1] The thicker the melanoma, the more serious the situation becomes.

Checking for Ulceration

The pathologist also examines the biopsy tissue to see if ulceration is present. Ulceration means the melanoma has grown through the top layer of skin and created an open wound on the surface.^[4] Sometimes this bleeding or wound is visible before the biopsy, but in other cases, it can only be detected when the tissue is viewed under a microscope. The presence of ulceration is significant because it indicates a more aggressive melanoma with a higher risk of spreading and recurring after treatment.^[4]

Assessing Mitotic Rate

Another factor pathologists evaluate is the mitotic rate, which measures how fast the cancer cells are dividing and multiplying.^[4] This is determined by counting the number of cells undergoing division in a specific area of the tumor tissue. A higher mitotic rate—meaning the cancer cells are dividing more rapidly—is associated with a poorer outlook, as faster-growing cancers are more likely to spread.^[4]

Lymph Node Evaluation

If the biopsy shows that the nodular melanoma is more than 1 millimeter thick, your doctor will likely recommend additional testing of your lymph nodes.^[1] Lymph nodes are small, bean-shaped structures that are part of your body’s immune system. They filter fluid and help fight infections. Cancer cells can travel through the lymphatic system and settle in lymph nodes, which is one way melanoma spreads beyond the original site.

To check whether the melanoma has reached your lymph nodes, doctors may perform a sentinel lymph node biopsy. This procedure identifies and removes the lymph node or nodes that are most likely to contain cancer cells if the melanoma has begun to spread.^[4] The status of the sentinel lymph nodes—whether they contain cancer cells or not—is one of the most important factors affecting prognosis and treatment planning.^[4]

If cancer has spread to nearby lymph nodes, the melanoma is classified as Stage III.^[1] The more lymph nodes that contain cancer cells, the more serious the situation becomes.^[4] When melanoma reaches distant lymph nodes or spreads to internal organs, it’s considered Stage IV disease.^[1]

Imaging Studies and Blood Tests

For melanomas that are more than 1 millimeter thick, doctors may recommend imaging studies to check whether the cancer has spread to other parts of your body.^[3] These tests might include CT scans (computed tomography), MRI scans (magnetic resonance imaging), or PET scans (positron emission tomography). These imaging techniques create detailed pictures of the inside of your body, allowing doctors to see whether melanoma has reached organs like the lungs, liver, brain, or bones.

Blood tests may also be performed as part of the diagnostic workup, especially if there’s concern that the melanoma has spread.^[3] While blood tests alone cannot diagnose melanoma, they can provide information about your overall health and organ function, which helps doctors plan treatment.

Diagnostics for Clinical Trial Qualification

When patients with nodular melanoma are considered for participation in clinical trials—research studies testing new treatments—they must undergo a standardized set of diagnostic tests. These tests serve two important purposes: they confirm that the patient has the specific type and stage of melanoma the trial is studying, and they establish a baseline measurement of the disease that researchers can use to evaluate whether the experimental treatment is working.

Staging and Classification

Clinical trials typically require precise staging of the melanoma before a patient can enroll. The staging process uses the information gathered from the biopsy—including tumor thickness, presence of ulceration, and mitotic rate—combined with results from lymph node biopsies and imaging studies.^[1] This comprehensive staging determines whether the melanoma is Stage 0, I, II, III, or IV, which helps researchers ensure they’re studying patients with similar disease characteristics.

Stage 0, also called melanoma in situ, means the cancer cells are only in the top layer of skin and haven’t spread at all.^[1] Stage I indicates a small, low-risk melanoma less than 2 millimeters thick with no evidence of spread. Stage II melanomas are thicker than 2 millimeters and have features suggesting higher risk, but still no evidence of spread. Stage III means the melanoma has reached nearby lymph nodes or nearby skin. Stage IV indicates the cancer has spread to distant lymph nodes, distant areas of skin, or internal organs.^[1]

Biomarker Testing

Many clinical trials, particularly those testing targeted therapies, require specific genetic testing of the melanoma tissue. Researchers examine the cancer cells for particular genetic mutations that might make the tumor respond to certain drugs. For example, scientists look for mutations in genes called NRAS, which are often found in nodular melanomas.^[3] Other genetic changes doctors might test for include mutations in genes called BRAF, which affect how the cancer cells grow and survive.

This genetic testing is performed on tissue samples obtained during biopsy. The laboratory uses sophisticated techniques to analyze the DNA of the cancer cells and identify specific mutations. If a patient has the genetic mutation that a clinical trial is targeting, they may be eligible to participate in that study. If they don’t have that particular mutation, they wouldn’t benefit from that specific experimental treatment and would need to look for other options.

Baseline Health Assessments

Before enrolling in clinical trials, patients typically need comprehensive health assessments to ensure they can safely tolerate the experimental treatment. These assessments often include blood tests to check kidney function, liver function, blood cell counts, and other indicators of overall health. Imaging scans document the extent and location of the melanoma, providing a baseline that researchers will use to measure whether the treatment is shrinking the tumors or preventing their growth.

Some trials also require specialized tests depending on the treatment being studied. For instance, if an experimental drug might affect heart function, patients may need an electrocardiogram (EKG) or echocardiogram before starting the trial. These cardiac tests measure the heart’s electrical activity and pumping function, establishing a baseline that doctors can monitor throughout the study.

Regular Monitoring During Trials

Once enrolled in a clinical trial, patients undergo regular diagnostic testing to monitor the melanoma’s response to treatment. This typically includes repeated imaging scans at scheduled intervals—perhaps every 6 to 12 weeks—to see whether tumors are shrinking, staying the same size, or growing. Blood tests are also performed regularly to check for side effects and monitor overall health. These ongoing assessments help researchers understand whether the experimental treatment is working and whether it’s safe for continued use.